Mastering Dato-DXd Toxicity: Prophylaxis for Stomatitis and Dry Eye Stomatitis and dry eye are amongst the most talked about toxicities with datopotamab deruxtecan. Drs. Iyengar and Hamilton explain why management hinges on true prophylaxis—initiating treatments before symptoms arise. FacebookXRedditPinterestEmail You may also like Video Dr. Neil Iyengar & Dr. Erika Hamilton – FirstLine TNBC: How TRO-Breast02 & ASCENT-03 Change the Game 1 min read Video Why TRO-Breast02 Included Higher-Risk ‘Bad Actors’ 1 min read Video Crossover Confusion: ASCENT-03 OS Data Complication 1 min read Video Trodelvy’s Dual Challenge: Managing Diarrhea and Neutropenia 1 min read Video Frontline mTNBC: How to Choose Between These Two ADCs 1 min read Video mTNBC ADC vs. Chemo: Is There Still a Place for Chemo in the ADC Era? 1 min read Recommended Videos Datopotamab Deruxtecan vs Sacituzumab Govitecan Explained – Dr. Bill Gradishar & Dr. Tiffany Traina 4 months ago DESTINY-Breast11, DESTINY-Breast05 & What Comes Next – Dr. Neil Iyengar & Dr. Komal Jhaveri 4 months ago Rethinking First-Line Metastatic HER2+ Therapy with T-DXd – Drs. Mouabbi, O’Shaughnessy & Rimawi 4 months ago Has HER2+ First-Line Treatment Officially Changed? – Dr. Neil Iyengar & Dr. Martin Dietrich 4 months ago
Video Dr. Neil Iyengar & Dr. Erika Hamilton – FirstLine TNBC: How TRO-Breast02 & ASCENT-03 Change the Game 1 min read
Datopotamab Deruxtecan vs Sacituzumab Govitecan Explained – Dr. Bill Gradishar & Dr. Tiffany Traina 4 months ago
DESTINY-Breast11, DESTINY-Breast05 & What Comes Next – Dr. Neil Iyengar & Dr. Komal Jhaveri 4 months ago
Rethinking First-Line Metastatic HER2+ Therapy with T-DXd – Drs. Mouabbi, O’Shaughnessy & Rimawi 4 months ago
Has HER2+ First-Line Treatment Officially Changed? – Dr. Neil Iyengar & Dr. Martin Dietrich 4 months ago